In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Additive prognostic value of copeptin and NT-proBNP in patients with acute heart failure

Session Poster Session 3

Speaker Konstantin A Krychtiuk

Event : Acute Cardiovascular Care 2016

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure
  • Session type : Poster Session

Authors : KA Krychtiuk (Vienna,AT), M Lenz (Vienna,AT), L Chi (Vienna,AT), C Zhang (Vienna,AT), MC Honeder (Vienna,AT), G Maurer (Vienna,AT), K Huber (Vienna,AT), J Wojta (Vienna,AT), G Heinz (Vienna,AT), WS Speidl (Vienna,AT)

KA Krychtiuk1 , M Lenz1 , L Chi1 , C Zhang1 , MC Honeder1 , G Maurer1 , K Huber2 , J Wojta1 , G Heinz1 , WS Speidl1 , 1Medical University of Vienna, Department of Internal Medicine II, Division of Cardiology - Vienna - Austria , 2Wilhelminen Hospital, 3rd Department of Internal Medicine, Cardiology and Emergency Medicine - Vienna - Austria ,

European Heart Journal Supplement ( 2010 ) 12 ( Supplement F ), F210

Background: Patients suffering from acute heart failure (AHF) requiring admission to an intensive care unit (ICU) have a poor prognosis. The C-terminal portion of provasopressin (Copeptin) represents a surrogate parameter for vasopressin, has been described as a marker for endogenous stress. Besides its use as a rule-out marker in patients with NSTE-ACS it has been described as a prognostic biomarker in patients with acute illness.
Purpose: The aim of this study was to analyze whether admission levels of copeptin are associated with 30-day survival in patients with AHF admitted to a cardiac ICU.
Methods: We included 90 consecutive patients with AHF admitted to our cardiovascular ICU (33% with cardiogenic shock, 21% with acutely decompensated HF and 46% of patients suffered from AHF after cardiac arrest). Blood was taken at admission, mtDNA levels were measured by real-time PCR while copeptin was measured by an automated sandwich immunofluorescent assay.
Results: Mean age was 62.1 ± 16.0, 76.7% of patients were male and median NT-proBNP levels were 4986 (1525 – 23842) pg/mL. 30-day survival was 64.4%. Non-survivors had significantly higher values of both copeptin (139.8 (44.7-311.2) pmol/L vs. 31.4 (17-77.1) pmol/L, p<0.001) and NT-proBNP (23718 (2981 – >35000) pg/mL vs. 3262 (1000.3 – 8212.3) pg/mL). Interestingly, copeptin and NT-proBNP showed additive prognostic value. When patients were stratified according to the median of NT-proBNP and copeptin, those with both copeptin and NT-proBNP levels above the median had the highest risk of dying (HR 4.6, p=0.003).
Conclusion: In a cohort of patients with AHF requiring ICU admission, copeptin levels measured at admission added prognostic value to NT-proBNP levels.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are